Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug;27(4):194-206.
doi: 10.1097/MED.0000000000000555.

Pharmacological therapies to address obesity in type 1 diabetes

Anna Casu  1 , Anika Bilal  1 , Richard E Pratley  1   2 ; Advancing Care for Type 1 Diabetes, Obesity Network (ACT1ON)
Affiliations
Review

Pharmacological therapies to address obesity in type 1 diabetes

Anna Casu et al. Curr Opin Endocrinol Diabetes Obes. 2020 Aug.

Abstract

Purpose of review: Obesity is increasing in prevalence among patients with type 1 diabetes (T1D) and is associated with insulin resistance and increased cardiovascular risk. The management of obesity in this population is complicated by defects in pancreatic islet hormone secretion and the effects of exogenous insulin treatment. Here, we review the effects of antiobesity medications and adjunct-to-insulin medications on body weight in T1D.

Recent findings: There is a profound evidence gap around the use of drugs for the treatment of obesity in T1D since systematic studies have not been performed in this population. Adjunctive-to-insulin therapy with certain antihyperglycemic agents leads to modest weight loss and reductions in insulin dose in T1D. However, only pramlintide has been approved in the United States for clinical use as adjunctive therapy in T1D.

Summary: The growing prevalence of obesity in T1D has created an unmet need for safe and effective therapies to treat overweight and obesity in this population. Currently, antiobesity medications are used off-label for the treatment of patients with T1D. Additional studies are needed to understand the role of these medications in the management of obesity in patients with T1D.

PubMed Disclaimer

References

    1. Flegal KM, Kruszon-Moran D, Carroll MD, et al. Trends in obesity among adults in the United States, 2005 to 2014. JAMA 2016; 315:2284–2291.
    1. Inoue Y, Qin B, Poti J, et al. Epidemiology of obesity in adults: latest trends. Curr Obes Rep 2018; 7:276–288.
    1. Skinner AC, Ravanbakht SN, Skelton JA, et al. Prevalence of obesity and severe obesity in US children. Pediatrics 2018; 141:e20173459.
    1. Gregg B, Connor CG, Ruedy KJ, et al. Body mass index changes in youth in the first year after type 1 diabetes diagnosis. J Pediatr 2015; 166:1265–1269.e1.
    1. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of high body mass index in US children and adolescents. JAMA 2010; 303:242–249.

Publication types

MeSH terms